Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year

Citations

2 articles found by citation matching

Search results

Filters applied: . Clear all
Page 1
slanDCs selectively accumulate in carcinoma-draining lymph nodes and marginate metastatic cells.
Vermi W, Micheletti A, Lonardi S, Costantini C, Calzetti F, Nascimbeni R, Bugatti M, Codazzi M, Pinter PC, Schäkel K, Tamassia N, Cassatella MA. Vermi W, et al. Nat Commun. 2014;5:3029. doi: 10.1038/ncomms4029. Nat Commun. 2014. PMID: 24398631 Free article.
Herein, by screening a large set of clinical samples, we demonstrate accumulation of slanDCs in metastatic tumour-draining lymph nodes (M-TDLN) from carcinoma patients. Remarkably, slanDCs are absent at the primary carcinoma site, …
Herein, by screening a large set of clinical samples, we demonstrate accumulation of slanDCs in metastatic tumour-draining
slanDCs in carcinoma-draining lymph nodes.
Vermi W, Lonardi S, Bugatti M, Calzetti F, Micheletti A, Cassatella MA. Vermi W, et al. Oncoimmunology. 2014 Jan 1;3(3):e28246. doi: 10.4161/onci.28246. Epub 2014 Mar 17. Oncoimmunology. 2014. PMID: 24843832 Free PMC article.
However, the role in anticancer immunosurveillance of 6-sulfo LacNAc-expressing DCs (slanDCs), a distinct population of circulating and tissue-resident pro-inflammatory DCs, is unclear. We have recently demonstrated the involvement of slanDCs in nodal immune respons …
However, the role in anticancer immunosurveillance of 6-sulfo LacNAc-expressing DCs (slanDCs), a distinct population of circulating a …
Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis.
Toma M, Wehner R, Kloß A, Hübner L, Fodelianaki G, Erdmann K, Füssel S, Zastrow S, Meinhardt M, Seliger B, Brech D, Noessner E, Tonn T, Schäkel K, Bornhäuser M, Bachmann MP, Wirth MP, Baretton G, Schmitz M. Toma M, et al. Oncoimmunology. 2015 Mar 2;4(6):e1008342. doi: 10.1080/2162402X.2015.1008342. eCollection 2015 Jun. Oncoimmunology. 2015. PMID: 26155414 Free PMC article.
In the present study, we investigated the characteristics of human 6-sulfo LacNAc (slan) DCs in clear cell renal cell carcinoma (ccRCC). slanDCs have been shown to display various tumor-directed properties and to accumulate in tumor-draining lymph n
In the present study, we investigated the characteristics of human 6-sulfo LacNAc (slan) DCs in clear cell renal cell carcinoma (ccRC …
Feedback